Quantcast

Seattle Genetics’s trial of tucatinib in HER2-positive breast cancer meets primary and secondary endpoints

Seattle Genetics’s trial of tucatinib in HER2-positive breast cancer has met primary and secondary endpoints, showing that the addition of tucatinib was superior to trastuzumab and capecitabine alone, and the company is planning NDA Submission to U.S. FDA for first quarter of 2020.

Read more

GlycoMimetics Announces Publication of Nature Cell Biology Paper Supporting Recently Announced Clinical Trial of GMI-1359

Preclinical studies indicatethat targeting both E-selectin and CXCR4 with a single compound couldimprove efficacy in the treatment of cancers that involve the bonemarrow such as AML and multiple myeloma or in solid tumors thatmetastasize to the bone, such as prostate cancer and breast cancer.

Read more